Risk Factors Update Summary
- Revenue decreased from 88% to 72% pharmaceutical and medical supply purchases.
- Withdrawal of a drug led to a decrease in revenue and net income.
- Increase in stock repurchase program authorization from $250 million to $500 million.
- Outstanding borrowings decreased from $1.094 billion to $0.088 billion.
- Compliance with DSCSA requirements and potential increased FDA enforcement could impact pharmacy costs.
- Failure to maintain effective internal control over operations could disrupt business.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1014739&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.